Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota / 医学前沿
Frontiers of Medicine
;
(4): 645-657, 2018.
Artículo
en Inglés
| WPRIM
| ID: wpr-771285
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is one of the most common metabolic diseases currently in the context of obesity worldwide, which contains a spectrum of chronic liver diseases, including hepatic steatosis, non-alcoholic steatohepatitis and hepatic carcinoma. In addition to the classical "Two-hit" theory, NAFLD has been recognized as a typical gut microbiota-related disease because of the intricate role of gut microbiota in maintaining human health and disease formation. Moreover, gut microbiota is even regarded as a "metabolic organ" that play complementary roles to that of liver in many aspects. The mechanisms underlying gut microbiota-mediated development of NAFLD include modulation of host energy metabolism, insulin sensitivity, and bile acid and choline metabolism. As a result, gut microbiota have been emerging as a novel therapeutic target for NAFLD by manipulating it in various ways, including probiotics, prebiotics, synbiotics, antibiotics, fecal microbiota transplantation, and herbal components. In this review, we summarized the most recent advances in gut microbiota-mediated mechanisms, as well as gut microbiota-targeted therapies on NAFLD.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Terapéutica
/
Resistencia a la Insulina
/
Ácidos y Sales Biliares
/
Colina
/
Suplementos Dietéticos
/
Metabolismo Energético
/
Enfermedad del Hígado Graso no Alcohólico
/
Trasplante de Microbiota Fecal
/
Microbioma Gastrointestinal
/
Intestinos
Límite:
Animales
/
Humanos
Idioma:
Inglés
Revista:
Frontiers of Medicine
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS